SCHEMBL68578

SCHEMBL68578

CC1Sc2ccccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.39
MAPT P10636 5/20 0.39
MAPK1 P28482 4/20 0.39
HPGD P15428 3/20 0.39
TSHR P16473 2/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
POLB P06746 3/20 0.38
S100A4 P26447 2/20 0.38
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37
LMNA P02545 3/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
HTR2B P41595 1/20 0.35
CDC25B P30305 1/20 0.35
PIM1 P11309 1/20 0.34
ALDH1A1 P00352 5/20 0.34
HSD17B10 Q99714 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13302892 1.00 ACHE (0.39) ACHEMAPTMAPK1HPGDTSHR
SCHEMBL28512628 0.78 MAPT (0.36) ACHEMAPTMAPK1HPGDTSHR
SCHEMBL10916939 0.77 MAPT (0.36) ACHEMAPTMAPK1HPGDTSHR
SCHEMBL13940537 0.77 MEN1 (0.41) MAPTMAPK1HPGDTSHRMEN1
SCHEMBL86293 0.76 EDNRB (0.41) MAPTMAPK1HPGDTSHRMEN1
SCHEMBL4255732 0.76 MAPT (0.36) ACHEMAPTMAPK1HPGDTSHR
SCHEMBL68863 0.76 MAPT (0.36) ACHEMAPTMAPK1HPGDTSHR
SCHEMBL68097 0.74 PIM1 (0.39) MAPTMAPK1HPGDTSHRMEN1
SCHEMBL4048521 0.74 MEN1 (0.38) MAPTMAPK1HPGDTSHRMEN1
SCHEMBL67625 0.74 ACHE (0.44) ACHEMAPTHPGDKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210299131-A1 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH NATIONAL INSTITUTES OF HEALTH 2021-09-30 US disclosed
US-10953017-B2 Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such SOUTHERN RESEARCH INSTITUTE (US) 2021-03-23 US disclosed
US-20200171040-A1 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH SOUTHERN RES INST (US) 2020-06-04 US disclosed
US-20190083505-A1 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH NATIONAL INSTITUTES OF HEALTH 2019-03-21 US disclosed
US-9980969-B2 Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such SOUTHERN RESEARCH INSTITUTE (US) 2018-05-29 US disclosed
WO-2017215627-A1 PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND 正大天晴药业集团股份有限公司 2017-12-21 WO disclosed
US-9801960-B2 Probe for a biological specimen and labelling method and screening method using the probe CANON KABUSHIKI KAISHA (JP) 2017-10-31 US disclosed
US-9801960-B2 Probe for a biological specimen and labelling method and screening method using the probe CANON KABUSHIKI KAISHA (JP) 2017-10-31 US disclosed
US-20160022691-A1 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH SOUTHERN RES INST (US) 2016-01-28 US disclosed
US-9211725-B2 Inkjet recording method and printed material FUJIFILM CORPORATION (JP) 2015-12-15 US disclosed
EP-2042573-A1 Ink composition FUJIFILM Corporation (JP) 2009-04-01 EP disclosed
EP-2042563-A1 Photocurable coating composition, and overprint and process for producing same FUJIFILM Corporation (JP) 2009-04-01 EP disclosed
US-20090081421-A1 PHOTOCURABLE COATING COMPOSITION, AND OVERPRINT AND PROCESS FOR PRODUCING SAME FUJIFILM CORPORATION (JP) 2009-03-26 US disclosed
US-20090081421-A1 PHOTOCURABLE COATING COMPOSITION, AND OVERPRINT AND PROCESS FOR PRODUCING SAME FUJIFILM CORPORATION (JP) 2009-03-26 US disclosed
US-20080239045-A1 INK SET FOR INKJET RECORDING AND INKJET RECORDING METHOD FUJIFILM CORPORATION (JP) 2008-10-02 US disclosed
US-20080239045-A1 INK SET FOR INKJET RECORDING AND INKJET RECORDING METHOD FUJIFILM CORPORATION (JP) 2008-10-02 US disclosed
EP-1975210-A1 Ink set for inkjet recording and inkjet recording method FUJIFILM Corporation (JP) 2008-10-01 EP disclosed
WO-2008109701-A1 NONLINEAR OPTICAL MATERIAL COMPOSITION AND METHOD OF MANUFACTURE NITTO DENKO CORPORATION (JP) 2008-09-12 WO disclosed
US-20080182031-A1 Sensitizing dye, an alpha-aminoketone or acyl phosphine oxide polymerization initiator and an ethylenically unsaturated bond-containing polymerizable compound FUJIFILM CORPORATION (JP) 2008-07-31 US disclosed
US-20080182031-A1 Sensitizing dye, an alpha-aminoketone or acyl phosphine oxide polymerization initiator and an ethylenically unsaturated bond-containing polymerizable compound FUJIFILM CORPORATION (JP) 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022691-A1 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH NFKBIA, NFRKB, TFEB ACHE 200/4885MAPT 54/4885MAPK1 1227/4885
US-20200171040-A1 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH NFKBIA, NFRKB, TFEB ACHE 217/4885MAPT 56/4885MAPK1 1419/4885
US-20190083505-A1 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH NFKBIA, NFRKB, TFEB ACHE 217/4885MAPT 56/4885MAPK1 1419/4885
US-20210299131-A1 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH NFKBIA, NFRKB, TFEB ACHE 217/4885MAPT 56/4885MAPK1 1419/4885
US-10953017-B2 Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such NFKBIA, NFRKB, TFEB ACHE 217/4885MAPT 56/4885MAPK1 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.